Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2016
Price : $35 *
At a glance
- Drugs Panitumumab (Primary) ; Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- 21 Sep 2016 Status changed from active, no longer recruiting to discontinued.
- 03 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 30 Jul 2015 NRAS wild type colorectal cancers was included along with KRAS in patient indication, study title and inclusion and exclusion criteria